BR112017005660A2 - novos ativadores de guanilato ciclase solúvel e sua utilização - Google Patents

novos ativadores de guanilato ciclase solúvel e sua utilização

Info

Publication number
BR112017005660A2
BR112017005660A2 BR112017005660A BR112017005660A BR112017005660A2 BR 112017005660 A2 BR112017005660 A2 BR 112017005660A2 BR 112017005660 A BR112017005660 A BR 112017005660A BR 112017005660 A BR112017005660 A BR 112017005660A BR 112017005660 A2 BR112017005660 A2 BR 112017005660A2
Authority
BR
Brazil
Prior art keywords
guanylate cyclase
soluble guanylate
cyclase activators
new soluble
pharmaceutical compositions
Prior art date
Application number
BR112017005660A
Other languages
English (en)
Portuguese (pt)
Inventor
Marie Jeanne Bouillot Anne
Dodic Nerina
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112017005660A2 publication Critical patent/BR112017005660A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
BR112017005660A 2014-09-19 2015-09-18 novos ativadores de guanilato ciclase solúvel e sua utilização BR112017005660A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19
PCT/IB2015/057219 WO2016042536A1 (en) 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use

Publications (1)

Publication Number Publication Date
BR112017005660A2 true BR112017005660A2 (pt) 2017-12-19

Family

ID=54238488

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005660A BR112017005660A2 (pt) 2014-09-19 2015-09-18 novos ativadores de guanilato ciclase solúvel e sua utilização

Country Status (21)

Country Link
US (2) US9938260B2 (cg-RX-API-DMAC7.html)
EP (1) EP3194384A1 (cg-RX-API-DMAC7.html)
JP (3) JP6678656B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170054508A (cg-RX-API-DMAC7.html)
CN (1) CN106687456B (cg-RX-API-DMAC7.html)
AU (1) AU2015319724B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017005660A2 (cg-RX-API-DMAC7.html)
CA (1) CA2961745A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000640A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017002506A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170102A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000073A (cg-RX-API-DMAC7.html)
EA (1) EA033697B1 (cg-RX-API-DMAC7.html)
IL (1) IL251094A0 (cg-RX-API-DMAC7.html)
MA (1) MA40583A (cg-RX-API-DMAC7.html)
MX (1) MX2017003621A (cg-RX-API-DMAC7.html)
PE (1) PE20170937A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500481A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701915TA (cg-RX-API-DMAC7.html)
WO (1) WO2016042536A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701835B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2685230C2 (ru) 2014-02-06 2019-04-17 Хептарес Терапьютикс Лимитед Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
US11331308B2 (en) 2016-10-11 2022-05-17 Bayer Pharma Aktiengesellschaft Combination containing sGC activators and mineralocorticoid receptor antagonists
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CN112055584A (zh) 2018-04-30 2020-12-08 拜耳公司 sGC活化剂和sGC刺激剂用于治疗认知障碍的用途
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CN119300815A (zh) 2022-06-09 2025-01-10 拜耳公司 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
JP5411703B2 (ja) * 2006-11-09 2014-02-12 アルコン リサーチ, リミテッド 薬物送達のための水不溶性ポリマーマトリクス
PE20091258A1 (es) * 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
CA2753434C (en) 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
EA033697B1 (ru) * 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение

Also Published As

Publication number Publication date
JP2020105189A (ja) 2020-07-09
CN106687456B (zh) 2019-12-03
AU2015319724B2 (en) 2018-05-10
US20170305888A1 (en) 2017-10-26
MA40583A (fr) 2016-03-24
ZA201701835B (en) 2018-12-19
DOP2017000073A (es) 2017-04-16
JP6678656B2 (ja) 2020-04-08
EA033697B1 (ru) 2019-11-18
MX2017003621A (es) 2017-07-14
JP2017527602A (ja) 2017-09-21
KR20170054508A (ko) 2017-05-17
WO2016042536A1 (en) 2016-03-24
US9938260B2 (en) 2018-04-10
PE20170937A1 (es) 2017-07-13
CA2961745A1 (en) 2016-03-24
CL2017000640A1 (es) 2017-10-06
JP6908747B2 (ja) 2021-07-28
SG11201701915TA (en) 2017-04-27
IL251094A0 (en) 2017-04-30
US10472350B2 (en) 2019-11-12
CO2017002506A2 (es) 2017-07-28
EP3194384A1 (en) 2017-07-26
CR20170102A (es) 2017-07-17
US20180194756A1 (en) 2018-07-12
JP2021155450A (ja) 2021-10-07
EA201790655A1 (ru) 2017-08-31
AU2015319724A1 (en) 2017-04-06
CN106687456A (zh) 2017-05-17
PH12017500481A1 (en) 2017-08-07

Similar Documents

Publication Publication Date Title
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
BR112018012707A2 (pt) inibidores da interação de menin-mll
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
BR112016006048A8 (pt) composições antimicrobianas
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2018000621A (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX376122B (es) Composiciones de plinabulina.
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
EA201791716A1 (ru) Фармацевтический состав
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
UY36150A (es) Derivados de naftiridinadiona
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
EA201691741A1 (ru) Фармацевтическая композиция
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
EA201991373A1 (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
BR112018004244A2 (pt) formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]